日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Switching from febuxostat to dotinurad, a novel selective urate reabsorption inhibitor, may substantially reduce serum urate levels, through URAT1 inhibition, potentially without adversely affecting ABCG2 function: findings from the SWITCH SURI study

从非布司他换用新型选择性尿酸重吸收抑制剂多替努拉,可通过抑制 URAT1 显著降低血清尿酸水平,且可能不会对 ABCG2 功能产生不利影响:SWITCH SURI 研究结果

Osonoi, Takeshi; Shirabe, Shinichiro; Saito, Miyoko; Hosoya, Mitsuru; Watahiki, Norie; Douguchi, Satako; Ofuchi, Kensuke; Katoh, Makoto

Imeglimin may affect hemoglobin A1c accuracy via prolongation of erythrocyte lifespan in patients with type 2 diabetes mellitus: insights from the INFINITY clinical trial

伊美格列明可能通过延长2型糖尿病患者红细胞寿命来影响糖化血红蛋白A1c的准确性:来自INFINITY临床试验的启示

Osonoi, Takeshi; Shirabe, Shinichiro; Saito, Miyoko; Hosoya, Mitsuru; Watahiki, Norie; Shiozawa, Nana; Douguchi, Satako; Ofuchi, Kensuke; Katoh, Makoto

Dapagliflozin Improves Erythropoiesis and Iron Metabolism in Type 2 Diabetic Patients with Renal Anemia

达格列净可改善伴有肾性贫血的2型糖尿病患者的红细胞生成和铁代谢

Osonoi, Takeshi; Shirabe, Shinichiro; Saito, Miyoko; Hosoya, Mitsuru; Watahiki, Norie; Douguchi, Satako; Ofuchi, Kensuke; Katoh, Makoto

Add-On Therapy with DPP-4 Inhibitors May Improve Renal Function Decline in α-Glucosidase Inhibitor and Metformin Users: A Retrospective Observational Study

DPP-4抑制剂联合治疗可能改善α-葡萄糖苷酶抑制剂和二甲双胍使用者的肾功能下降:一项回顾性观察研究

Osonoi, Takeshi; Saito, Miyoko; Koda, Naoya; Douguchi, Satako; Nakano, Takako; Ofuchi, Kensuke; Katoh, Makoto

Four-year sequential nerve conduction changes since first visit in Japanese patients with early type 2 diabetes

日本早期2型糖尿病患者自首次就诊以来四年的连续神经传导变化

Kobori, Mariko; Yagihashi, Soroku; Shiina, Norie; Shiozawa, Nana; Haginoya, Akiko; Ojima, Misato; Douguchi, Satako; Tamasawa, Atsuko; Saitou, Miyoko; Baba, Masayuki; Osonoi, Takeshi